Psoriasis and smoking: Links and risks

Psoriasis: Targets and Therapy

Volumn 6, Issue , 2016, Pages 65-71

  Naldi, Luigi ^a,b  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^b Italian Group for Epidemiological Research in Dermatology (GISED)   (Italy)

Author keywords

Comorbidities; Nicotine dependence; Onset; Prognosis; Psoriasis; Risk; Smoking

Indexed keywords

BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; DERMATOLOGIST; ENVIRONMENTAL EXPOSURE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INFLAMMATORY BOWEL DISEASE; LONG TERM EXPOSURE; MOLECULAR PATHOLOGY; MORTALITY; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO DEPENDENCE; TUMOR SUPPRESSOR GENE;

EID: 85043410189     PISSN: None     EISSN: 2230326X     Source Type: Journal    
DOI: 10.2147/PTT.S85189     Document Type: Review

References (59)

1. US Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking- Attributable Disease: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
2. Brandt AM. The Cigarette Century: The Rise, Fall, and Deadly Persistence of the Product That Defined America. New York, NY: Basic Books; 2007.
3. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans: Tobacco Smoke and Involuntary Smoking. Vol 83. Lyon, France: International Agency for Research on Cancer; 2004.
4. Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66(12):1378-1391.
5. Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. Lancet. 2015;385(9979): 1778-1788.
6. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372-377.
7. Rodgman A, Perfetti TA. The Chemical Components of Tobacco and Tobacco Smoke. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2009.
8. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.
9. Tanner JA, Chenoweth MJ, Tyndale RF. Pharmacogenetics of nicotine and associated smoking behaviors. Curr Top Behav Neurosci. 2015;23:37-86.
10. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control. 2003;12(4):424-430.
11. Bekki K, Uchiyama S, Ohta K, Inaba Y, Nakagome H, Kunugita N. Carbonyl compounds generated from electronic cigarettes. Int J Environ Res Public Health. 2014;11(11):11192-11200.
12. Mucha L, Stephenson J, Morandi N, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med. 2006;3(4):279-291.
13. Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2479-2485.
14. Shopland DR. Historical perspective: the low tar lie. Tob Control. 2001;10(Suppl 1):i1-i3.
15. Benowitz NL. Smokeless tobacco as a nicotine delivery device: harm or harm reduction? Clin Pharmacol Ther. 2011;90(4):491-493.
16. Farsalinos KE, Le Houezec J. Regulation in the face of uncertainty: the evidence on electronic nicotine delivery systems (e-cigarettes). Risk Manag Healthc Policy. 2015;8:157-167.
17. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372(4):392-394.
18. Naldi L, Mercuri SR. Smoking and psoriasis: from epidemiology to pathomechanisms. J Invest Dermatol. 2009;129(12):2741-2743.
19. Gilbert DG, Gilbert BO. Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. Behav Genet. 1995;25(2):133-147.
20. Caporaso N, Gu F, Chatterjee N, et al. Genomewide and candidate gene association study of cigarette smoking behaviors. PLoS One. 2009;4:e4653.
21. Lutz SM, Hokanson JE. Genetic influences on smoking and clinical disease. Understanding behavioral and biological pathways with mediation analysis. Ann Am Thorac Soc. 2014;11(7):1082-1083.
22. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction. 2003;98(1):23-31.
23. Loukola A, Hallfors J, Korhonen T, Kaprio J. Genetics and smoking. Curr Addict Rep. 2014;1(1):75-82.
24. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304-314.
25. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61-67.
26. La Vecchia C, Gallus S, Naldi L. Tobacco and skin disease. Dermatology. 2005;211(2):81-83.
27. Jin Y, Yang S, Zhang F, et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol. 2009,23(2):132-137.
28. Yin XY, Cheng H, Wang WJ, et al. TNIP1/ ANXA6 and CSMD1 variants interacting with cigarette smoking, alcohol intake affect risk of psoriasis. J Dermatol Sci. 2013;70(2):94-98.
29. Quan C, Zhu KJ, Zhang C, et al. Combined effects of the BDNF rs6265 (Val66Met) polymorphism and environment risk factors on psoriasis vulgaris. Mol Biol Rep. 2014;41(10):7015-7022.
30. Krämer U, Esser C. Cigarette smoking, metabolic gene polymorphism, and psoriasis. J Invest Dermatol. 2006;126(3):693-694.
31. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol. 2011;165(6):1162-1168.
32. Yanagita M, Kobayashi R, Kojima Y, Mori K, Murakami S. Nicotine modulates the immunological function of dendritic cells through peroxisome proliferator-activated receptor-γ upregulation. Cell Immunol. 2012;274(1-2):26-33.
33. Jeong SH, Park JH, Kim JN, et al. Up-regulation of TNF-α secretion by cigarette smoke is mediated by Egr-1 in HaCaT human keratinocytes. Exp Dermatol. 2010;19(8):e206-e212.
34. Csordas A, Bernhard D. The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol. 2013;10(4)219-230.
35. Fortes C, Mastroeni S, Leffondré K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141(12): 1580-1584.
36. Gupta MA, Gupta AK, Watteel GN. Cigarette smoking in men may be a risk factor for increased psoriasis of the extremities. Br J Dermatol. 1996;135(5):859-860.
37. Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis. 2000;66(5):348-352.
38. Kinahan CE, Mazloom S, Fernandez AP. Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective casecontrol study. Br J Dermatol. 2015;172(2):428-436.
39. Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20-31.
40. Di Lernia V, Ricci C, Lallas A, Ficarelli E. Clinical predictors of nonresponse to any tumor necrosis factor (TNF) blockers: a retrospective study. J Dermatolog Treat. 2014;25(1):73-74.
41. Zhu KJ, Quan C, Zhang C, et al. Combined effect between CHRNB3- CHRNA6 region gene variant (rs6474412) and smoking in psoriasis vulgaris severity. Gene. 2014;544(2):123-127.
42. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3(2):121-128.
43. Naldi L, Chatenoud L. Psoriasis et tumeurs: un lien plus qu’un hasard. [Psoriasis and cancer: more than a chance link]. Ann Dermatol Venereol. 2006;133(3):221-223. French.
44. Rakkhit T, Wong B, Nelson TS, Hansen CB, Papenfuss JS, Panko J. Time to development of psoriatic arthritis decreases with smoking prior to psoriasis onset and increases with smoking after psoriasis onset. J Invest Dermatol. 2007;127(Suppl 2):52.
45. Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37(5):426-430.
46. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(6):804-808.
47. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358-1361.
48. Højgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130-2136.
49. Skudutyte-Rysstad R, Slevolden EM, Hansen BF, Sandvik L Preus HR. Association between moderate to severe psoriasis and periodontitis in a Scandinavian population. BMC Oral Health. 2014;14:139.
50. Antal M, Braunitzer G, Mattheos N, Gyulai R, Nagy K. Smoking as a permissive factor of periodontal disease in psoriasis. PLoS One. 2014;14:139.
51. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961-969.
52. Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF α: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880-888.
53. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from smoking in developed countries: indirect estimates from national vital statistics. Lancet. 1992;339(8804):1268-1278.
54. McIvor A, Kayser J, Assaad JM, et al. Best practices for smoking cessation interventions in primary care. Can Respir J. 2009;16(4):129-134.
55. Dobbie F, Hiscock R, Leonardi-Bee J, et al. Evaluating long-term outcomes of NHS stop smoking services (ELONS): a prospective cohort study. Health Technol Assess. 2015;19(95):1-156.
56. Norcross JC, Krebs PM, Prochaska JO. Stages of change. J Clin Psychol. 2011;67(2):143-154.
57. Fiore MC, Baker TB. Clinical practice. Treating smokers in the health care setting. N Engl J Med. 2011;365(13):1222-1231.
58. Nelson PA, Keyworth C, Chisholm A, et al. Identification and Management of Psoriasis-Associated Co-morbidiTy (IMPACT) Team. “In someone’s clinic but not in mine” - clinicians’ views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. Br J Dermatol. 2014;171(5):1116-1122.
59. Naldi L. Lifestyle intervention should be an essential component of medical care for skin disease: a challenging task. Br J Dermatol. 2014;171(5): 934-935.